{"id":750780,"date":"2023-04-25T08:44:50","date_gmt":"2023-04-25T12:44:50","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-present-at-the-h-c-wainwright-bioconnect-investor-conference-at-nasdaq\/"},"modified":"2023-04-25T08:44:50","modified_gmt":"2023-04-25T12:44:50","slug":"cabaletta-bio-to-present-at-the-h-c-wainwright-bioconnect-investor-conference-at-nasdaq","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-present-at-the-h-c-wainwright-bioconnect-investor-conference-at-nasdaq\/","title":{"rendered":"Cabaletta Bio to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ"},"content":{"rendered":"<div class=\"mw_release\">\n<p>PHILADELPHIA, April  25, 2023  (GLOBE NEWSWIRE) &#8212; Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference at NASDAQ on Tuesday, May 2, 2023 at 1:30 p.m. ET in New York, NY.<\/p>\n<p>A live webcast of the presentation will be available on the News and Events section of the Company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Fchkqr1JvHapUNj1E8BmE_X23dLwhU_5bhKZqJ-2lNaBcAFGI_1vnfV9jDYZPOaRdTPrMDlSxHS7lUCaLih6I_LbuoGtLsZlxXHFcREN7pM=\" rel=\"nofollow noopener\" target=\"_blank\">www.cabalettabio.com<\/a>. Replays of the presentation will be available on the website for 30 days.<\/p>\n<p>\n        <strong>About Cabaletta Bio<\/strong><br \/>\n        <br \/>Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA\u2122 platform encompasses two strategies: the CARTA (Chimeric Antigen Receptor T cells for Autoimmunity) strategy, with CABA-201, a 4-1BB-containing fully human CD19-CAR T, as the lead product candidate being evaluated in lupus nephritis and systemic lupus erythematosus without renal involvement, and the CAART (Chimeric AutoAntibody Receptor T cells) strategy, with multiple clinical-stage candidates, including DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for MuSK myasthenia gravis. The expanding CABA\u2122 platform may offer potentially curative therapies for patients with a broad range of autoimmune diseases. Cabaletta Bio\u2019s headquarters and labs are located in Philadelphia, PA.<\/p>\n<p>\n        <strong>Contacts:<\/strong>\n      <\/p>\n<p>Anup Marda<br \/>Chief Financial Officer<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fSuM4SdnsC-qHrxOVTSOMRWanJJjxjUtRe46918Uvi0LaFt1ApFbtiNyzWyMVv3YocvMVmyw9HcTfj-St9SeGYlHabNj7xofg52r0mcfd5cD_hcn43VXISHSjwUY-cbG\" rel=\"nofollow noopener\" target=\"_blank\">investors@cabalettabio.com<\/a><\/p>\n<p>Sarah McCabe<br \/>Stern Investor Relations, Inc.<br \/>212-362-1200<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=slh7Oq6zd4xVHDLrmZWKB9gB2oseDe_Tsvh9Zy7hRqSHj4zlkYpn484pJBZWOoC6XNP7sFjUcyneH60FtUIq2H8BoW1_1XxENkWACucuAn4=\" rel=\"nofollow noopener\" target=\"_blank\">sarah.mccabe@sternir.com<\/a><\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyMzk0OCM1NTUyNzU1IzIxMjUwMzA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MjExNTg0NGMtZDYzOS00MWNjLWE3NzMtYmNjN2VhZjhlNDE4LTExMzY2MDE=\/tiny\/Cabaletta-Bio.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>PHILADELPHIA, April 25, 2023 (GLOBE NEWSWIRE) &#8212; Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference at NASDAQ on Tuesday, May 2, 2023 at 1:30 p.m. ET in New York, NY. A live webcast of the presentation will be available on the News and Events section of the Company\u2019s website at www.cabalettabio.com. Replays of the presentation will be available on the website for 30 days. About Cabaletta Bio Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-present-at-the-h-c-wainwright-bioconnect-investor-conference-at-nasdaq\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cabaletta Bio to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-750780","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cabaletta Bio to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-present-at-the-h-c-wainwright-bioconnect-investor-conference-at-nasdaq\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cabaletta Bio to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PHILADELPHIA, April 25, 2023 (GLOBE NEWSWIRE) &#8212; Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference at NASDAQ on Tuesday, May 2, 2023 at 1:30 p.m. ET in New York, NY. A live webcast of the presentation will be available on the News and Events section of the Company\u2019s website at www.cabalettabio.com. Replays of the presentation will be available on the website for 30 days. About Cabaletta Bio Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and &hellip; Continue reading &quot;Cabaletta Bio to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-present-at-the-h-c-wainwright-bioconnect-investor-conference-at-nasdaq\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-25T12:44:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyMzk0OCM1NTUyNzU1IzIxMjUwMzA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cabaletta-bio-to-present-at-the-h-c-wainwright-bioconnect-investor-conference-at-nasdaq\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cabaletta-bio-to-present-at-the-h-c-wainwright-bioconnect-investor-conference-at-nasdaq\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cabaletta Bio to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ\",\"datePublished\":\"2023-04-25T12:44:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cabaletta-bio-to-present-at-the-h-c-wainwright-bioconnect-investor-conference-at-nasdaq\\\/\"},\"wordCount\":275,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cabaletta-bio-to-present-at-the-h-c-wainwright-bioconnect-investor-conference-at-nasdaq\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyMzk0OCM1NTUyNzU1IzIxMjUwMzA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cabaletta-bio-to-present-at-the-h-c-wainwright-bioconnect-investor-conference-at-nasdaq\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cabaletta-bio-to-present-at-the-h-c-wainwright-bioconnect-investor-conference-at-nasdaq\\\/\",\"name\":\"Cabaletta Bio to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cabaletta-bio-to-present-at-the-h-c-wainwright-bioconnect-investor-conference-at-nasdaq\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cabaletta-bio-to-present-at-the-h-c-wainwright-bioconnect-investor-conference-at-nasdaq\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyMzk0OCM1NTUyNzU1IzIxMjUwMzA=\",\"datePublished\":\"2023-04-25T12:44:50+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cabaletta-bio-to-present-at-the-h-c-wainwright-bioconnect-investor-conference-at-nasdaq\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cabaletta-bio-to-present-at-the-h-c-wainwright-bioconnect-investor-conference-at-nasdaq\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cabaletta-bio-to-present-at-the-h-c-wainwright-bioconnect-investor-conference-at-nasdaq\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyMzk0OCM1NTUyNzU1IzIxMjUwMzA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyMzk0OCM1NTUyNzU1IzIxMjUwMzA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cabaletta-bio-to-present-at-the-h-c-wainwright-bioconnect-investor-conference-at-nasdaq\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cabaletta Bio to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cabaletta Bio to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-present-at-the-h-c-wainwright-bioconnect-investor-conference-at-nasdaq\/","og_locale":"en_US","og_type":"article","og_title":"Cabaletta Bio to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ - Market Newsdesk","og_description":"PHILADELPHIA, April 25, 2023 (GLOBE NEWSWIRE) &#8212; Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference at NASDAQ on Tuesday, May 2, 2023 at 1:30 p.m. ET in New York, NY. A live webcast of the presentation will be available on the News and Events section of the Company\u2019s website at www.cabalettabio.com. Replays of the presentation will be available on the website for 30 days. About Cabaletta Bio Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and &hellip; Continue reading \"Cabaletta Bio to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-present-at-the-h-c-wainwright-bioconnect-investor-conference-at-nasdaq\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-25T12:44:50+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyMzk0OCM1NTUyNzU1IzIxMjUwMzA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-present-at-the-h-c-wainwright-bioconnect-investor-conference-at-nasdaq\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-present-at-the-h-c-wainwright-bioconnect-investor-conference-at-nasdaq\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cabaletta Bio to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ","datePublished":"2023-04-25T12:44:50+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-present-at-the-h-c-wainwright-bioconnect-investor-conference-at-nasdaq\/"},"wordCount":275,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-present-at-the-h-c-wainwright-bioconnect-investor-conference-at-nasdaq\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyMzk0OCM1NTUyNzU1IzIxMjUwMzA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-present-at-the-h-c-wainwright-bioconnect-investor-conference-at-nasdaq\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-present-at-the-h-c-wainwright-bioconnect-investor-conference-at-nasdaq\/","name":"Cabaletta Bio to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-present-at-the-h-c-wainwright-bioconnect-investor-conference-at-nasdaq\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-present-at-the-h-c-wainwright-bioconnect-investor-conference-at-nasdaq\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyMzk0OCM1NTUyNzU1IzIxMjUwMzA=","datePublished":"2023-04-25T12:44:50+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-present-at-the-h-c-wainwright-bioconnect-investor-conference-at-nasdaq\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-present-at-the-h-c-wainwright-bioconnect-investor-conference-at-nasdaq\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-present-at-the-h-c-wainwright-bioconnect-investor-conference-at-nasdaq\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyMzk0OCM1NTUyNzU1IzIxMjUwMzA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyMzk0OCM1NTUyNzU1IzIxMjUwMzA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cabaletta-bio-to-present-at-the-h-c-wainwright-bioconnect-investor-conference-at-nasdaq\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cabaletta Bio to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/750780","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=750780"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/750780\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=750780"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=750780"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=750780"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}